Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 381

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Open access
Tie, Jeanne, Cohen, Joshua D, Wang, Yuxuan, Li, Lu, Christie, Michael, Simons, Koen, Elsaleh, Hany, Kosmider, Suzanne, Wong, Rachel, Yip, Desmond, Lee, Margaret, Tran, Ben, Rangiah, David, Burge, Matthew, Goldstein, David, Singh, Madhu, Skinner, Iain, Faragher, Ian, Croxford, Matthew, Bampton, Carolyn, Haydon, Andrew, Jones, Ian T, S Karapetis, Christos, Price, Timothy, Schaefer, Mary J, Ptak, Jeanne, Dobbyn, Lisa, Silliman, Natallie, Kinde, Isaac, Tomasetti, Cristian, Papadopoulos, Nickolas, Kinzler, Kenneth, Volgestein, Bert, Gibbs, Peter·2019·Gut

Abstract

Objective: For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. Design: We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4–10 weeks after surgery. Somatic mutations in individual patient’s tumour were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. We then designed personalised assays to quantify ctDNA in plasma samples. Patients received adjuvant therapy at clinician discretion, blinded to the ctDNA results. Results: We analysed 462 serial plasma samples from 159 patients. ctDNA was detectable in 77%, 8.3% and 12% of pretreatment, postchemoradiotherapy and postsurgery plasma samples. Significantly worse recurrence-free survival was seen if ctDNA was detectable after chemoradiotherapy (HR 6.6; P<0.001) or after surgery (HR 13.0; P<0.001). The estimated 3-year recurrence-free survival was 33% for the postoperative ctDNA-positive patients and 87% for the postoperative ctDNA-negative patients. Postoperative ctDNA detection was predictive of recurrence irrespective of adjuvant chemotherapy use (chemotherapy: HR 10.0; P<0.001; without chemotherapy: HR 22.0; P<0.001). Postoperative ctDNA status remained an independent predictor of recurrence-free survival after adjusting for known clinicopathological risk factors (HR 6.0; P<0.001). Conclusion: Postoperative ctDNA analysis stratifies patients with LARC into subsets that are either at very high or at low risk of recurrence, independent of conventional clinicopathological risk factors. ctDNA analysis could potentially be used to guide patient selection for adjuvant chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-315852

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 381

Metadata

Authors
Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., Lee, M., Tran, B., Rangiah, D., Burge, M., Goldstein, D., Singh, M., Skinner, I., Faragher, I., Croxford, M., Bampton, C., Haydon, A., Jones, I. T., S Karapetis, C., Price, T., Schaefer, M. J., Ptak, J., Dobbyn, L., Silliman, N., Kinde, I., Tomasetti, C., Papadopoulos, N., Kinzler, K., Volgestein, B., & Gibbs, P.
Venue
Gut
Publisher
BMJ
Published
2018-02-02
Volume
68
Issue
4
Pages
663-671
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2786388608
Cited by
381
References
25
FWCI
10.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. https://app.cochat.ai/papers/10.1136/gutjnl-2017-315852
The paper
Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., Lee, M., Tran, B., Rangiah, D., Burge, M., Goldstein, D., Singh, M., Skinner, I., Faragher, I., Croxford, M., . . . Gibbs, P. (2019). Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. https://doi.org/10.1136/gutjnl-2017-315852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.